DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

Siemens launches RT Pro edition of MAGNETOM Sola at ASTRO MR system assists in radiation therapy treatment planning

RaySearch introduces machine learning in RayStation at ASTRO First machine learning applications on RayStation platform

New Philips MR and CT scanners debut at ASTRO CT system, Big Bore RT, and Ingenia MR-RT take aim at radiotherapy outcomes

Brainlab debuts RT patient positioning and monitoring system at ASTRO Monitors both external and internal motion

For this cancer, proton therapy is no better than IMRT

par John R. Fischer , Staff Reporter
Proton therapy (PT) may not be a safer bet compared to conventional radiation when it comes to lowering toxicity associated with non-small cell lung cancer (NSCLC).

At least that’s what researchers at the University of Texas MD Anderson Cancer Center and Massachusetts General Hospital say in a new study comparing dose distribution of 3-D passive scattering proton therapy (PT) and intensity-modulated radiation therapy (IMRT), finding no decline in risks, such as radiation pneumonitis, when using the former type of treatment. Their findings were published in the Journal of Clinical Oncology.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“There is no doubt that there is dosimetric advantage in protons compared with photons. Whether the dosimetric advantage will translated to clinical benefit or not depends on many factors including how best use this new form of radiation," Dr. Zhongxing Liao, the lead author of the study and a professor of Radiation Oncology at the University of Texas MD Anderson Cancer Center, told HCB News. "Our trial showed that, using an outdated way, passively scattered proton beam or 3-D conformal proton, to deliver proton, we were not able to realize the dosimetric advantage of the proton on lung; therefore, we did not reduce radiation pneumonitis."

The presumption that proton therapy is superior to conventional radiation due to its more-targeted form of delivery have led some to conclude that randomized trials comparing the two are unnecessary, inappropriate and unethical.

Researchers tested this hypothesis in a Bayesian trial in which 149 patients with inoperable NSCLC were randomly selected to undergo IMRT or PSPT with the objective being to determine if PSPT patients showed a lower risk of grade ≥ 3 RP or local failure (LF).

PSPT was found to expose less lung tissue at 5-10 GY (RBE) doses but more at doses of 20 GY (RBE) or higher. No benefits in grade ≥ 3 RP or LF were found in these patients with locally advanced NSCLC.

A one-year follow-up found the PSPT group had a 10.5 percent rate of ≥ 3 RP compared with 6.5 percent of IMRT patients.

Rates of LF were 10.9 percent at one year for patients who underwent IMRT, compared to 10.5 percent of PSPT patients. Combined RP and LF rates at one year were 17.4 percent and 21.1 percent following IMRT and PSPT, respectively.

Though not the main focus, median survival for PSPT patients was 26.1 months and for IMRT, 29.5.

The findings here could make many skeptical of growth predictions for the proton therapy market, which is expected to almost double in value by 2022. They also contrast with a recent study that compared PT and IMRT in the treatment of prostate cancer, finding higher survival rates and less complications induced by radiation exposure among patients who underwent PT.

“The trial tells us that, when investing for proton centers, one needs to be aware of the issues encountered in our trial and be prepared to address them," said Liao. "Adequate engineering, physics, clinical and research support is critical to ensure the success of the proton centers.”

Despite these results, the use of PSPT was found to reduce heart exposure to radiation at levels between 5 and 80 Gy, as well as heart volume, with its impact on cardiac toxicity and overall survival currently under study.

Sparing the heart for overall survival is currently being evaluated in a phase III randomized lung trial that will provide evidence on the use of proton therapy for lung cancer, while a phase II study is comparing the effects of IMRT to the next-generation proton technique intensity-modulated proton therapy. Both will help in providing more information on the comparisons between proton therapy and photon treatments.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2018 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS